{"id":16931,"date":"2025-04-08T14:47:32","date_gmt":"2025-04-08T14:47:32","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/blog\/exploring-new-paths-in-adc-development\/"},"modified":"2026-06-10T08:50:22","modified_gmt":"2026-06-10T08:50:22","slug":"exploring-new-paths-in-adc-development","status":"publish","type":"blog","link":"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/exploring-new-paths-in-adc-development\/","title":{"rendered":"Exploring new paths in ADC development"},"content":{"rendered":"\n<p><strong>Catch up on our <a href=\"https:\/\/youtu.be\/eFpplhWH6Tk\" target=\"_blank\" rel=\"noreferrer noopener\">ADC development series<\/a> on YouTube to hear more expert insights.<\/strong><\/p>\n\n\n\n<p>Antibody-drug conjugates (ADCs) represent an important approach to targeted cancer therapy, combining the specificity of antibodies with the potent cytotoxicity of small-molecule drugs. Despite their promise, clinical ADC development has faced numerous challenges, including limited therapeutic windows and off-target toxicity. To address these challenges, we\u2019re now rethinking traditional approaches and shifting our focus from antibody-centric to payload-centric strategies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading has-text-2-xl-font-size\"><strong>A Holistic Approach to ADC Development<\/strong><\/h2>\n\n\n\n<p>Historically, ADC development has largely centred around optimizing the antibody component and subsequently conjugating a cytotoxic payload\/linker combination. The assumption was that the specificity of the antibody would allow selective delivery the payload and this would translate directly to clinical tolerability. Whilst crucial, this focus has often overshadowed other equally important aspects, such as conjugation site and technique, sample heterogeneity, linker stability and, more recently, payload selection.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.sygnaturediscovery.com\/drug-discovery\/integrated-drug-discovery\/antibody-drug-conjugates\/\">A holistic approach to ADC development<\/a> recognizes the need to balance all components\u2014antibody, conjugation, linker, and payload\u2014to create a more effective and safer therapeutic agent. This involves refining antibody specificity and minimizing the biophysical impact of conjugation, whilst also designing linkers that are stable in circulation and facilitate efficient payload release at the disease site. And by optimizing how the linker is conjugated, we can enhance drug-to-antibody ratios (DARs) and sample homogeneity, ultimately improving the overall ADC therapeutic profile.<\/p>\n\n\n\n<h2 class=\"wp-block-heading has-text-2-xl-font-size\"><strong>A Shift from Antibody-Centric to Payload-Centric Thinking<\/strong><\/h2>\n\n\n\n<p>Whilst ADC research traditionally focussed on the antibody, recent insights indicate that the payload plays an equally crucial role in determining the efficacy and safety of ADCs. As these therapeutics evolve, we are witnessing a move from traditional cytotoxic payloads toward more mechanistically targeted agents with defined, specific modes of action, tailored toward certain patient populations. Indeed, in oncology, payload selection is becoming more meticulously aligned with the cancer type and disease context, ensuring maximum therapeutic impact with minimal collateral damage.<\/p>\n\n\n\n<p>Furthermore, a robust understanding of how the payload interacts with cellular mechanisms delivers a second level of selectivity and can also inform better decisions in linker design, conjugation chemistry, and dose optimization. This paradigm shift emphasizes the importance of selecting potent and targeted agents that are effective at low doses and aligned with the intended patient population.<\/p>\n\n\n\n<h2 class=\"wp-block-heading has-text-2-xl-font-size\"><strong>Key Take Away<\/strong><\/h2>\n\n\n\n<p>Incorporating a holistic and payload-centric perspective in ADC development not only broadens therapeutic possibilities but also addresses the limitations seen in earlier generations of ADCs. By evolving from an antibody-centric mindset, we are becoming better positioned to harness the full potential of ADC technology\u2014offering hope for more precise and effective treatments, for cancer and other diseases, in the future.<\/p>\n\n\n\n<h3 class=\"wp-block-heading has-text-2-xl-font-size\"><strong>Read the next part in our ADC development blog series:<\/strong><\/h3>\n\n\n\n<p>Part 2: <a href=\"https:\/\/www.sygnaturediscovery.com\/news-and-events\/blog\/evolving-role-of-med-chem-in-adc-development\/\">What\u2019s the Evolving Role of Medicinal Chemistry in ADC Development?<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading has-text-2-xl-font-size\"><strong>About the Authors<\/strong><\/h3>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-28f84493 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image size-full is-style-rounded is-style-rounded--1\" style=\"margin-right:var(--wp--preset--spacing--20);margin-left:var(--wp--preset--spacing--20)\"><img loading=\"lazy\" decoding=\"async\" width=\"342\" height=\"360\" src=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/03\/Allan-Jordan_VP_Oncology_UK-2.webp\" alt=\"\" class=\"wp-image-16582\" srcset=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/03\/Allan-Jordan_VP_Oncology_UK-2.webp 342w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/03\/Allan-Jordan_VP_Oncology_UK-2-285x300.webp 285w\" sizes=\"(max-width: 342px) 100vw, 342px\"><\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image size-full is-style-rounded is-style-rounded--2\" style=\"margin-right:var(--wp--preset--spacing--20);margin-left:var(--wp--preset--spacing--20)\"><img loading=\"lazy\" decoding=\"async\" width=\"342\" height=\"360\" src=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/01\/Joshua-Greally_Scientific-BD-Manager_ADC-Lead_UK.webp\" alt=\"\" class=\"wp-image-11790\" srcset=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/01\/Joshua-Greally_Scientific-BD-Manager_ADC-Lead_UK.webp 342w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/01\/Joshua-Greally_Scientific-BD-Manager_ADC-Lead_UK-285x300.webp 285w\" sizes=\"(max-width: 342px) 100vw, 342px\"><\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\"><\/div>\n<\/div>\n\n\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-28f84493 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\"><section class=\"Pegasus__Container w-full   relative h-fit  text-content-dark mobile-stacking-standard is-layout-flow wp-block-pegasus-container-is-layout-flow\" style=\"  padding-right:var(--wp--preset--spacing--20);padding-left:var(--wp--preset--spacing--20); \">\n\t        \n\t\n\t\t\t\t\t\t\n\t\t        \t\t\n\t\t\t\t\t\t\t\n\t\t\t<div class=\"inner relative h-full is-flex-layout flex flex-col justify-start  w-full\">\n\n<p>Dr. <a href=\"https:\/\/www.linkedin.com\/in\/allan-jordan-0191884?originalSubdomain=uk\" type=\"link\" id=\"https:\/\/www.linkedin.com\/in\/allan-jordan-0191884?originalSubdomain=uk\">Allan Jordan<\/a> is Vice President of Oncology Drug Discovery at Sygnature Discovery. He has extensive experience developing targeted therapeutics and advancing integrated drug discovery programs. Drawing on a background in medicinal chemistry, he focuses on optimizing payload properties and designing antibody-drug conjugates to improve clinical tolerability, ensuring that novel therapeutics can successfully navigate the complexities of late-stage development.<\/p>\n\n<\/div>\n\t\t\n\t        <\/section>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\"><section class=\"Pegasus__Container w-full   relative h-fit  text-content-dark mobile-stacking-standard is-layout-flow wp-block-pegasus-container-is-layout-flow\" style=\"  padding-right:var(--wp--preset--spacing--20);padding-left:var(--wp--preset--spacing--20); \">\n\t        \n\t\n\t\t\t\t\t\t\n\t\t        \t\t\n\t\t\t\t\t\t\t\n\t\t\t<div class=\"inner relative h-full is-flex-layout flex flex-col justify-start  w-full\">\n\n<p>Dr. <a href=\"https:\/\/www.linkedin.com\/in\/joshua-greally-13964a98\/?originalSubdomain=uk\" type=\"link\" id=\"https:\/\/www.linkedin.com\/in\/joshua-greally-13964a98\/?originalSubdomain=uk\">Joshua Greally<\/a>\u00a0is ADC Lead at Sygnature Discovery. With a foundation in medicinal chemistry, bioconjugation and ADC discovery, he guides the strategic design of next-generation antibody-drug conjugates. He specializes in taking a holistic approach to ADC development, matching antigen biology with novel payloads to overcome clinical tolerability issues and enhance targeted delivery mechanisms. Ultimately helping to bridge the gap between early discovery and successful IND submission.\u00a0<\/p>\n\n<\/div>\n\t\t\n\t        <\/section>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\"><\/div>\n<\/div>\n\n\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>\u00a0<\/p>\n\n\n<section class=\"Pegasus__Container w-full   relative h-fit  text-content-dark mobile-stacking-standard is-layout-flow wp-block-pegasus-container-is-layout-flow\" style=\"   \">\n\t        \n\t\n\t\t\t\t\t\t\n\t\t        \t\t\n\t\t\t\t\t\t\t\n\t\t\t<div class=\"inner relative h-full is-flex-layout flex flex-col justify-start  w-full\"><\/div>\n\t\t\n\t        <\/section>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"featured_media":17446,"template":"","category":[1409,820],"class_list":["post-16931","blog","type-blog","status-publish","has-post-thumbnail","hentry","category-adcs","category-modalites"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Exploring new paths in ADC development - Sygnature<\/title>\n<meta name=\"description\" content=\"Clinical ADC development has faced numerous challenges, to address these challenges, we\u2019re now rethinking traditional approaches. Learn More.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/exploring-new-paths-in-adc-development\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exploring new paths in ADC development - Sygnature\" \/>\n<meta property=\"og:description\" content=\"Clinical ADC development has faced numerous challenges, to address these challenges, we\u2019re now rethinking traditional approaches. Learn More.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/exploring-new-paths-in-adc-development\/\" \/>\n<meta property=\"og:site_name\" content=\"Sygnature\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-10T08:50:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/06\/ADC_Feature-image.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1062\" \/>\n\t<meta property=\"og:image:height\" content=\"597\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/blog\\\/exploring-new-paths-in-adc-development\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/blog\\\/exploring-new-paths-in-adc-development\\\/\",\"name\":\"Exploring new paths in ADC development - Sygnature\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/blog\\\/exploring-new-paths-in-adc-development\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/blog\\\/exploring-new-paths-in-adc-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/ADC_Feature-image.webp\",\"datePublished\":\"2025-04-08T14:47:32+00:00\",\"dateModified\":\"2026-06-10T08:50:22+00:00\",\"description\":\"Clinical ADC development has faced numerous challenges, to address these challenges, we\u2019re now rethinking traditional approaches. Learn More.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/blog\\\/exploring-new-paths-in-adc-development\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/blog\\\/exploring-new-paths-in-adc-development\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/blog\\\/exploring-new-paths-in-adc-development\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/ADC_Feature-image.webp\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/ADC_Feature-image.webp\",\"width\":1062,\"height\":597},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/blog\\\/exploring-new-paths-in-adc-development\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/page-daccueil\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exploring new paths in ADC development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"name\":\"Sygnature Discovery\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\"},\"alternateName\":\"Sygnature\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\",\"name\":\"Sygnature\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"width\":1,\"height\":1,\"caption\":\"Sygnature\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Exploring new paths in ADC development - Sygnature","description":"Clinical ADC development has faced numerous challenges, to address these challenges, we\u2019re now rethinking traditional approaches. Learn More.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/exploring-new-paths-in-adc-development\/","og_locale":"fr_CA","og_type":"article","og_title":"Exploring new paths in ADC development - Sygnature","og_description":"Clinical ADC development has faced numerous challenges, to address these challenges, we\u2019re now rethinking traditional approaches. Learn More.","og_url":"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/exploring-new-paths-in-adc-development\/","og_site_name":"Sygnature","article_modified_time":"2026-06-10T08:50:22+00:00","og_image":[{"width":1062,"height":597,"url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/06\/ADC_Feature-image.webp","type":"image\/webp"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimation du temps de lecture":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/exploring-new-paths-in-adc-development\/","url":"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/exploring-new-paths-in-adc-development\/","name":"Exploring new paths in ADC development - Sygnature","isPartOf":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/exploring-new-paths-in-adc-development\/#primaryimage"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/exploring-new-paths-in-adc-development\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/06\/ADC_Feature-image.webp","datePublished":"2025-04-08T14:47:32+00:00","dateModified":"2026-06-10T08:50:22+00:00","description":"Clinical ADC development has faced numerous challenges, to address these challenges, we\u2019re now rethinking traditional approaches. Learn More.","breadcrumb":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/exploring-new-paths-in-adc-development\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sygnaturediscovery.com\/fr\/blog\/exploring-new-paths-in-adc-development\/"]}]},{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/exploring-new-paths-in-adc-development\/#primaryimage","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/06\/ADC_Feature-image.webp","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/06\/ADC_Feature-image.webp","width":1062,"height":597},{"@type":"BreadcrumbList","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/exploring-new-paths-in-adc-development\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sygnaturediscovery.com\/fr\/page-daccueil\/"},{"@type":"ListItem","position":2,"name":"Exploring new paths in ADC development"}]},{"@type":"WebSite","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","name":"Sygnature Discovery","description":"","publisher":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization"},"alternateName":"Sygnature","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sygnaturediscovery.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization","name":"Sygnature","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","width":1,"height":1,"caption":"Sygnature"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/blog\/16931","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/blog"}],"about":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/types\/blog"}],"version-history":[{"count":0,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/blog\/16931\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media\/17446"}],"wp:attachment":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media?parent=16931"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/category?post=16931"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}